Cargando…

Colorectal Cancer Is Associated with a Deficiency of Lipoxin A(4), an Endogenous Anti-inflammatory Mediator

Unresolved inflammation, due to insufficient production of proresolving anti-inflammatory lipid mediators, can lead to tumorigenesis. Among these mediators, lipoxin A(4) (LXA(4)) has potent anti-carcinogenic properties, and may serve as key target for modulating inflammation-associated cancer like c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haojing, Zeng, Ji, Huang, Wei, Xu, Qiang, Ye, Duyun, Sun, Rui, Zhang, Dongxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6746129/
https://www.ncbi.nlm.nih.gov/pubmed/31528237
http://dx.doi.org/10.7150/jca.32456
Descripción
Sumario:Unresolved inflammation, due to insufficient production of proresolving anti-inflammatory lipid mediators, can lead to tumorigenesis. Among these mediators, lipoxin A(4) (LXA(4)) has potent anti-carcinogenic properties, and may serve as key target for modulating inflammation-associated cancer like colorectal cancer. The purpose of present study was to clarify the roles of LXA(4) in colorectal cancer. We investigated the effects and underlying mechanisms of LXA(4) in colorectal cancer and its relationship with tumor-associated inflammation and immune microenvironment by employing clinical samples and mouse colorectal cancer cell line CT26-bearing tumor model as well as colorectal cancer cells. It was found that colorectal cancer is associated with dysregulation of immune microenvironment and deficiency of LXA(4) that could play different roles at different stages of tumor growth: inhibiting early but promoting late tumor growth. Analysis of peripheral immune cells in subcutaneous xenograft mice model disclosed that early LXA(4) treatment induced lymphocytes and inhibited neutrophils and monocytes, while late LXA(4) treatment induced neutrophils but inhibited lymphocytes. Detailed analysis of tumor microenvironment revealed that early LXA(4) treatment could inhibit inflammatory mediators expressions and leukocytes infiltration into tumor. Furthermore, LXA(4) could suppress the expressions of p-ERK, p-P38 and NF-κB in subcutaneous xenograft. Additionally, LXA(4) could inhibit the proliferation and migration of colorectal cancer cells, and, meanwhile, inhibit the proliferation and migration of colorectal cancer cells stimulated by activated macrophage-conditioned media. These findings suggest that colorectal cancer is associated with a deficiency of LXA(4) that could suppress colorectal cancer via modulating tumor-associated inflammation and immune microenvironment as well as inhibiting colorectal cancer cell development.